ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1827

Psoriatic Arthritis, Female Sex and Increased Baseline Skin Severity Are Associated with Drug Persistence in Ustekinumab-Treated Patients with Psoriasis in the BADBIR Cohort
Abstract Number: 1828

Safety Profile of Ixekizumab for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis up to 3 Years: An Updated Integrated Safety Analysis
Abstract Number: 1829

Pharmacological Treatment of Enthesitis – A Systematic Review on the Efficacy of the Available Options
Abstract Number: 1830

Discontinuation of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis and Psoriasis
Abstract Number: 1831

Predictors of Response, Adverse Events and Treatment Retention in Psoriatic Arthritis Patients Treated with Golimumab in a Prospective, Observational Registry
Abstract Number: 1832

Secukinumab Therapy in Biologic-naïve vs. Biologic-experienced Patients: Real-world Effectiveness, Persistence and Safety Results from the Rheumatic Diseases Portuguese Registry
Abstract Number: 1833

Risk of Major Adverse Cardiovascular Events (MACE) with Biologic and Targeted Synthetic Antirheumatic Agents in Psoriatic Arthritis: A Systematic Review and Network Meta-analysis
Abstract Number: 1834

To What Extent Do Clinical Features of PsA Predict Achievement of Minimal Disease Activity at Week 24: A Post Hoc Analysis of the Phase III Clinical Trial Program of Guselkumab in a Bio-naïve Patient Population
Abstract Number: 1835

Secukinumab Effects on Cardiometabolic Risk and Systemic Inflammation in Patients with Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis: Results from Post Hoc Analyses of Pooled Data from 19 Phase 3/4 Clinical Studies
Abstract Number: 1836

Outcomes Linked to Eligibility for Stem Cell Transplantation Trials in Diffuse Cutaneous Systemic Sclerosis
Abstract Number: 1837

KL-6, CXCL11 and CTGF Are Potential Biomarkers in Response to Treatment in CTD-ILD
Abstract Number: 1838

Further Construct Validation of the
Abstract Number: 1839

Hispanic Patients with Systemic Sclerosis Have More Severe Disease and Higher Mortality: A Longitudinal Cohort Study
Abstract Number: 1840

Can Dual-energy CT Lung Perfusion Detect Abnormalities at the Level of Lung Circulation in Systemic Sclerosis (SSc) ? Preliminary Experience in 101 Patients
Abstract Number: 1841

Presence of Autoantibodies to Dense-Fine-Speckled 70 (DFS70) Do Not Necessarily Rule out Connective Tissue Diseases

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].